Autoimmune hemolytic anemia risk factors

Revision as of 23:20, 6 April 2018 by Shyam Patel (talk | contribs)
Jump to navigation Jump to search

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia risk factors

CDC on Autoimmune hemolytic anemia risk factors

Autoimmune hemolytic anemia risk factors in the news

Blogs on Autoimmune hemolytic anemia risk factors

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Risk Factors

In the majority of cases of autoimmune hemolytic anemia, the etiology is not found, and patients have no predisposing risk factors. However, there are certain conditions that can predispose a person to develop autoimmune hemolytic anemia. These conditions have an immunologic or autoimmune basis, with aberrant immune activation that results in generation of autoantibodies against oneself. The best autoimmune-related known risk factor is systemic lupus erythematosus (SLE).[1] SLE is a multisystem rheumatologic disease that is characterized by production of anti-double stranded DNA and anti-nuclear antibodies, with resultant autoimmune-mediated damage to a variety of organs including the kidneys, brain, skin, and peripheral blood.[1]

  • Immunotherapy: Another risk factor for autoimmune hemolytic anemia is the use of immunotherapeutic agents to treat an underlying cancer.
    • Pembrolizumab: This is a humanized monoclonal antibody against PD-1.
    • Nivolumab: This is a monoclonal antibody against PD-1.
    • Ipilimumab: This is a humanized monoclonal antibody against PD-1.
    • Atezolizumab: This is a humanized monoclonal antibody against PD-L1 on tumor cells. This medication is FDA-approved for patients with advanced or metastatic urothelial cancer who are ineligible for cisplatin-based therapy or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapy. It is also approved for patients with metastatic non-small cell lung cancer who have had disease progression on platinum-based chemotherapy.
    • Avelumab: This is a humanized monoclonal IgG1 antibody against PD-L1 on tumor cells. This medication is FDA-approved for patients above the age of 12 with metastatic Merkel cell carcinoma.

References

  1. 1.0 1.1 Fujii J, Kurahashi T, Konno T, Homma T, Iuchi Y (2015). "Oxidative stress as a potential causal factor for autoimmune hemolytic anemia and systemic lupus erythematosus". World J Nephrol. 4 (2): 213–22. doi:10.5527/wjn.v4.i2.213. PMC 4419130. PMID 25949934.

Template:Hematology


Template:WikiDoc Sources